^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    SNB-101

    i
    Other names: SNB-101, SNB 101, SN-38
    Company:
    Boryung Group, SN BioSci
    Drug class:
    DNA topoisomerase inhibitor
    Related drugs:
    1year
    Dose-finding Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SNB-101(SN-38) in Patients With Tumors (clinicaltrials.gov)
    P1, N=36, Not yet recruiting, SN BioScience | Trial completion date: Dec 2023 --> Jun 2025 | Trial primary completion date: May 2023 --> Dec 2024
    Trial completion date • Trial primary completion date • Metastases
    |
    SNB-101